Zydus Cadila gets DCGI nod for emergency use of ‘Virafin’ to treat moderate Covid-19

Prameyanews English

Published By : Prameya News Bureau | April 23, 2021 IST

New Delhi, April 23: Zydus Cadila today got emergency use nod from the Drug Controller General of India (DCGI) for ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults in the country. Virafin was found to be successful in treating Covid-19 patients diagnosed with moderate symptoms. The single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients the company claimed adding that "91.15% of patients treated with PegIFN were RT-PCR negative by day 7".

News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp

You Might Also Like

More From Related News

Copyright © 2024 - Summa Real Media Private Limited. All Rights Reserved.